Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

被引:0
|
作者
Joanna Achinger-Kawecka
Fatima Valdes-Mora
Phuc-Loi Luu
Katherine A. Giles
C. Elizabeth Caldon
Wenjia Qu
Shalima Nair
Sebastian Soto
Warwick J. Locke
Nicole S. Yeo-Teh
Cathryn M. Gould
Qian Du
Grady C. Smith
Irene R. Ramos
Kristine F. Fernandez
Dave S. Hoon
Julia M. W. Gee
Clare Stirzaker
Susan J. Clark
机构
[1] Garvan Institute of Medical Research,Epigenetics Research Laboratory, Genomics and Epigenetics Theme
[2] UNSW Sydney,St. Vincent’s Clinical School, Faculty of Medicine
[3] The Kinghorn Cancer Centre,Cancer Theme
[4] John Wayne Cancer Institute,Department of Translational Molecular Medicine
[5] Cardiff University,Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences
来源
Nature Communications | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer.
引用
收藏
相关论文
共 50 条
  • [21] Loss of estrogen receptor alters drug responsiveness and supports a basal-like phenotype in endocrine-resistant HER2+/ER+ breast cancer
    Bahnassy, Shaymaa
    Stires, Hillary
    Jin, Lu
    Tam, Stanley
    Dunn, Yasmin J.
    Kohrn, Brendan F.
    Loeb, Lawrence A.
    Balachandran, Manasi
    Podar, Mircea
    Mccoy, Matthew D.
    Beckman, Robert A.
    Riggins, Rebecca B.
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Discovery of potent and selective novel small molecule drugs to target estrogen receptor mutants in endocrine-resistant breast cancer
    Devakrishnan, Anil Kumar
    Madasu, Chandrashekhar
    Fuqua, Suzanne A. W.
    Matzuk, Martin M.
    Palaniappan, Murugesan
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
    Guest, Stephanie K.
    Ribas, Ricardo
    Pancholi, Sunil
    Nikitorowicz-Buniak, Joanna
    Simigdala, Nikiana
    Dowsett, Mitch
    Johnston, Stephen R.
    Martin, Lesley-Ann
    PLOS ONE, 2016, 11 (06):
  • [24] Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer
    Deng, Xiangping
    Deng, Xiaofei
    Ning, Wentao
    Xin, Lilan
    Li, Qiuzi
    Hu, Zhiye
    Xie, Baohua
    Liang, Kaiwei
    Min, Chang
    Dong, Chune
    Huang, Jian
    Zhou, Hai-Bing
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (16) : 11094 - 11117
  • [25] FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer
    Castillo-Castrejon, Marisol
    Sankofi, Barbara Mensah
    Murguia, Stevi Johnson
    Udeme, Abasi-ama
    Cen, Hoaning Howard
    Xia, Yi Han
    Thomas, Nisha S.
    Berry, William L.
    Jones, Kenneth L.
    Richard, Vincent R.
    Zahedi, Rene P.
    Borchers, Christoph H.
    Johnson, James D.
    Wellberg, Elizabeth A.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [26] Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo
    Xie, Baohua
    Yin, Zhinang
    Hu, Zhiye
    Lv, Junhui
    Du, Chuanqian
    Deng, Xiangping
    Huang, Yuan
    Li, Qiuzi
    Huang, Jian
    Liang, Kaiwei
    Zhou, Hai-Bing
    Dong, Chune
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (10) : 6631 - 6651
  • [27] FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer
    Marisol Castillo-Castrejon
    Barbara Mensah Sankofi
    Stevi Johnson Murguia
    Abasi-ama Udeme
    Hoaning Howard Cen
    Yi Han Xia
    Nisha S. Thomas
    William L. Berry
    Kenneth L. Jones
    Vincent R. Richard
    Rene P. Zahedi
    Christoph H. Borchers
    James D. Johnson
    Elizabeth A. Wellberg
    Breast Cancer Research, 25
  • [28] Changes in expression of estrogen receptor and coregulatory proteins in the acquisition of endocrine-resistant breast cancer, as demonstrated using an in vitro cell model.
    Parkes, A
    Ponchel, F
    Burdall, S
    Farmery, S
    Speirs, V
    BRITISH JOURNAL OF CANCER, 2002, 86 : S22 - S22
  • [29] Recurrent mutations at estrogen receptor binding sites alter chromatin topology and distal gene expression in breast cancer
    Jiekun Yang
    Xiaolong Wei
    Turan Tufan
    Cem Kuscu
    Hayrunnisa Unlu
    Saadia Farooq
    Elif Demirtas
    Bryce M. Paschal
    Mazhar Adli
    Genome Biology, 19
  • [30] Recurrent mutations at estrogen receptor binding sites alter chromatin topology and distal gene expression in breast cancer
    Yang, Jiekun
    Wei, Xiaolong
    Tufan, Turan
    Kuscu, Cem
    Unlu, Hayrunnisa
    Farooq, Saadia
    Demirtas, Elif
    Paschal, Bryce M.
    Adli, Mazhar
    GENOME BIOLOGY, 2018, 19